Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, 22 October 2020: Reference is made to the stock exchange announcement by Targovax ASA (OSE:TRVX) ("Targovax" or the "Company"), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumor, on 14 October 2020, regarding a successfully completed private placement of new shares in the Company (the "Private Placement").
The NOK 1,034,482.80 share capital increase pertaining to the Private Placement has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 8,652,059.20, divided into 86,520,592 shares, each with a par value of NOK 0.10.
The new shares issued in the Private Placement will be listed on the Oslo Stock Exchange today.
For further information, please contact:
Torbjørn Furuseth, CFO
Phone: +47 932 11 101
Email: torbjorn.furuseth@targovax.com